Expert guidance on 510(k), De Novo, PMA submissions, and 21 CFR compliance. Written to help medical device companies navigate FDA regulatory pathways with confidence.
**Summary:** Medical device manufacturers must submit a new 510(k) when modifications—firmware updates, material changes, label updates—could significantly affect safety or effectiveness. FDA enforcement includes warning letters, recalls, and product seizures for unauthorized changes.
AI requests pause 510(k) review timelines until complete responses are submitted, and submissions requiring multiple AI cycles average 200+ FDA days—double the standard review goal. Understanding what triggers AI requests (missing data, performance testing gaps, software deficiencies, biocompatibility issues) and crafting thorough, well-organized responses is critical to avoiding delays and NSE decisions.
Biocompatibility testing for 510(k) submissions requires a risk-based evaluation framework per FDA's 2016 ISO 10993-1 guidance, not a fixed checklist—mistakes in scope, standard application, or data presentation commonly cause 3-6 month delays. Success depends on a robust Biological Evaluation Plan and Report that justify endpoint selection based on device contact type, duration, materials, and lifecycle factors.
Manufacturers of 510(k)-cleared medical devices must determine whether modifications require a new submission or can be documented internally—getting this wrong risks regulatory action or unnecessary delays. FDA's 2017 guidance provides a decision framework based on whether changes "could affect" device safety or effectiveness, placing the burden on manufacturers to document their analysis regardless of outcome.